PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
19855096-2	2010	Lobeline interacts with nicotinic receptor subtypes, dopamine transporters (DATs), and vesicular monoamine transporters (VMAT2s).	Lobeline	0-8	solute carrier family 18 member A2	Homo sapiens	121-126	
20876747-1	2011	Lobeline attenuates the behavioral effects of methamphetamine via inhibition of the vesicular monoamine transporter (VMAT2).	Lobeline	0-8	solute carrier family 18 member A2	Homo sapiens	117-122	
18191815-3	2008	Lobeline caused release of [(3)H]dopamine to a similar extent as reserpine (VMAT-2 inhibitor), but was less efficacious than methamphetamine or dopamine.	Lobeline	0-8	solute carrier family 18 member A2	Homo sapiens	76-82	
18191815-5	2008	These results suggest that lobeline has unique properties at the DAT and VMAT-2 which may make it useful as a pharmacotherapeutic to treat methamphetamine abuse.	Lobeline	27-35	solute carrier family 18 member A2	Homo sapiens	73-79	
16107155-1	2005	(-)-Lobeline (2R,6S,10S), an antagonist at nicotinic acetylcholine receptors (nAChRs), inhibits the neurochemical and behavioral effects of methamphetamine and inhibits dopamine transporter (DAT) and vesicular monoamine transporter (VMAT2) function.	Lobeline	0-12	solute carrier family 18 member A2	Homo sapiens	233-238	
16107155-6	2005	Generally, all of these analogues had lower affinities at alpha4beta2 and alpha7 nAChRs compared to lobeline, thereby increasing selectivity for VMAT2.	Lobeline	100-108	solute carrier family 18 member A2	Homo sapiens	145-150	
15102929-5	2004	High concentrations of lobeline induced a statistically significant release of [3H]DA from HEK-hDAT-hVMAT2 cells, but only in the absence of DHTB, suggesting an hVMAT2-mediated effect.	Lobeline	23-31	solute carrier family 18 member A2	Homo sapiens	100-106	
15102929-5	2004	High concentrations of lobeline induced a statistically significant release of [3H]DA from HEK-hDAT-hVMAT2 cells, but only in the absence of DHTB, suggesting an hVMAT2-mediated effect.	Lobeline	23-31	solute carrier family 18 member A2	Homo sapiens	161-167	
15121762-10	2004	Lobelane and ketoalkene were 5-fold more potent (Ki = 0.92 and 1.35 microM, respectively) than lobeline (Ki = 5.46 microM) in inhibiting [3H]methoxytetrabenazine binding to VMAT2 in vesicle preparations.	Lobeline	95-103	solute carrier family 18 member A2	Homo sapiens	173-178